天然物をシードとする制がんリード化合物の合成化学的創製研究  [in Japanese] Exploration for Anti-cancer Leads through Synthetic Approach Utilizing Biologically Active Natural Products as Seed Principles  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

Aiming at exploration for new anti-cancer leads utilizing biologically active natural products as seed principles, several synthetic lead compounds have been disclosed through structure-activity relationship analyses by means of a synthetic approach. 1) The absolute structure of callystatin A, potent cytotoxic polyketide, was established by comparative analysis of the CD spectra of synthetic model compounds and our first total synthesis. Furthermore, structure-activity relationship analysis using synthetic analogs revealed α,β-unsaturated δ-lactone to be pharmacophore functionality. According to the synthetic protocol of callystatin A, the first synthesis of leptomycin B, congeneric anti-tumor polyketide, was achieved to determine its absolute structure. 2) By evaluation for biological potency of synthesized amide analogs of potent cytotoxic depsipeptide arenastatin A, metabolism of 15,20-ester linkage resulted in significant reduction of anti-tumor efficacy in vivo. Modification of this ester linkage gave rise to promising leads with stability in serum as well as moderate cytotoxicity. 3) Synthesis of 4-deacetoxycongener of agosterol A, an MDR modulating polyhydroxysterol, was conducted from readily available ergosterol by way of regioselective reductive-cleavage of epoxy function developed by our group. In addition, 4-deacetoxycongener exhibited MDR modulating activity similar to agosterol A.

Journal

  • Natural medicines

    Natural medicines 56(3), 73-77, 2002-06-20

    日本生薬学会

References:  14

  • <no title>

    MURAKAMI N.

    Bioorg. Med. Chem. 8, 1680-1690, 2000

    Cited by (1)

  • <no title>

    MURAKAMI N.

    Bioorg. Med. Chem. 9, 57-67, 2001

    Cited by (1)

  • <no title>

    MURAKAMI N.

    Tetrahedron 56, 8548-8555, 2000

    Cited by (1)

  • <no title>

    MURAKAMI N.

    Med. Chem. Lett. 10, 4473-4476, 2000

    Cited by (1)

  • <no title>

    MURAKAMI N.

    Chem. Eur. J. 7, 2663-2670, 2001

    Cited by (1)

  • <no title>

    KOBAYASHI M.

    Tetrahedron Lett. 38, 2859-2862, 1997

    DOI Cited by (2)

  • <no title>

    MURAKAMI N.

    Tetrahedron Lett. 38, 5533-5536, 1997

    Cited by (3)

  • <no title>

    MURAKAMI N.

    Tetrahedron Lett. 39, 2349-2352, 1998

    DOI Cited by (1)

  • <no title>

    KOBAYASHI M.

    Tetrahedron Lett. 39, 8291-8294, 1998

    Cited by (2)

  • <no title>

    MURAKAMI N.

    Tetrahedron 57, 4323-4336, 2001

    DOI Cited by (1)

  • <no title>

    AOKI S.

    Tetrahedron Lett. 39, 6303-6306, 1998

    DOI Cited by (4)

  • <no title>

    MURAKAMI N.

    Bioorg. Med. Chem. Lett. 10, 2521-2524, 2000

    DOI Cited by (1)

  • <no title>

    MURAKAMI N.

    Tetrahedron Lett. 41, 1941-1943, 2001

    Cited by (1)

  • <no title>

    MURAKAMI N.

    Bioorg. Med. Chem. Lett. 10, 2629-2632, 2000

    DOI Cited by (1)

Codes

  • NII Article ID (NAID)
    110008732173
  • NII NACSIS-CAT ID (NCID)
    AN10438628
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    13403443
  • NDL Article ID
    6207315
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z19-375
  • Data Source
    CJP  NDL  NII-ELS  IR 
Page Top